Cyberport and Hong Kong API Co-host Forum to Promote Trustworthy AI Applications in Healthcare

Stock News
08/27

Cyberport and the Hong Kong Association of Pharmaceutical Industries (HKAPI) jointly organized the "Maintaining Trust: Artificial Intelligence and Data Privacy in Healthcare" forum, focusing on how artificial intelligence (AI) drives innovation and transformation in the healthcare industry while exploring the data privacy and security challenges encountered in AI implementation. Simultaneously, Cyberport announced that its AI Supercomputing Centre (AISC) has successfully obtained ISO/IEC 27001:2022 information security certification, marking that the development and application of AI technologies using AISC resources can now provide data security and privacy protection that meets international standards, providing strong confidence for various industries to advance intelligent transformation.

Cyberport CEO Peter Yan stated that AI is the core driving force behind healthcare innovation, while data privacy serves as the cornerstone for the sustainable development of medical technology. Both elements need to work closely together and mutually reinforce each other as medical technology advances. He expressed hope that through this forum, leveraging insights from experts across various fields, more healthcare AI applications can be implemented to ultimately benefit every citizen.

Following AISC's certification under the ISO international information security management standard, Cyberport will continue to use AISC as its core foundation to further build a comprehensive AI ecosystem encompassing computing power, data, general and specialized large models, providing comprehensive support for innovative research and development and applications, promoting intelligent development across numerous industries including healthcare.

HKAPI Senior Executive Director Susanna Chan noted that artificial intelligence holds tremendous potential in improving administrative efficiency, optimizing healthcare processes, enhancing diagnostic accuracy, and enabling personalized treatment. At the same time, special attention must be paid to the sensitive nature of medical data, ensuring that while continuously exploring advances in medical technology, patient privacy is maintained and public trust is preserved.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10